Holen Sie sich die Stockscreener-App
107.55
2.48%
2.54
Schlusskurs vom Vortag:
$105.01
Offen:
$106.75
24-Stunden-Volumen:
305.44K
Relative Volume:
0.41
Marktkapitalisierung:
$6.25B
Einnahmen:
$507.44M
Nettoeinkommen (Verlust:
$-187.69M
KGV:
-32.88
EPS:
-3.271
Netto-Cashflow:
$-39.06M
1W Leistung:
+2.27%
1M Leistung:
-10.62%
6M Leistung:
+31.96%
1J Leistung:
+9.34%
1-Tages-Spanne:
$104.78
$108.90
1-Wochen-Bereich:
$102.12
$110.13
52-Wochen-Spanne:
$73.16
$130.23
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
107.54 | 6.10B | 507.44M | -187.69M | -39.06M | -3.271 |
ABT
Abbott Laboratories
|
102.51 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
328.77 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.69 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.59 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Glaukos Corp. Experiences Evaluation Revision Amidst Mixed Market Signals and Volatility - Markets Mojo
Alex Thurman: ‘Phenomenal Year’ for Glaukos - Orange County Business Journal
Price-Driven Insight from (GKOS) for Rule-Based Strategy - Stock Traders Daily
Aug Chart Watch: Does Glaukos Corporation stock have upside surprise potential2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Glaukos breaks ground on $80M R&D, manufacturing facility in Alabama - MSN
Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock - MarketBeat
Glaukos SVP Thurman sells $267k in GKOS stock - Investing.com
Glaukos (NYSE: GKOS) president reports new stock and option grants - Stock Titan
GLAUKOS (GKOS) CDO Tomas Navratil earns performance RSU stock awards - Stock Titan
Glaukos Corporation (NYSE:GKOS): Is Breakeven Near? - 富途牛牛
Glaukos launches Epioxa, boosts growth in corneal treatments - MSN
Riverbridge Partners LLC Sells 34,475 Shares of Glaukos Corporation $GKOS - MarketBeat
Assenagon Asset Management S.A. Has $20.59 Million Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos (GKOS) Is Up 5.5% After Launching Incision-Free Epioxa Therapy For KeratoconusWhat's Changed - simplywall.st
Vanguard realigns reporting; Vanguard subsidiaries to report GKOS holdings (GKOS) - Stock Titan
Insider Selling: Glaukos (NYSE:GKOS) CFO Sells 1,521 Shares of Stock - MarketBeat
Glaukos CFO Thurman sells $160k in shares By Investing.com - Investing.com Australia
Glaukos CFO Thurman sells $160k in shares - Investing.com
Glaukos (NYSE: GKOS) CDO has shares withheld to cover tax obligations - Stock Titan
Glaukos (NYSE: GKOS) CFO sale and tax share withholdings detailed - Stock Titan
Glaukos (NYSE: GKOS) insider plans sale of 2,511 vested shares - Stock Titan
Glaukos (GKOS) affiliate files to sell 1,521 shares after vesting - Stock Titan
Glaukos Corp Stock Faces Monthly Pressure Amid Analyst Optimism and Glaucoma Innovation Push - AD HOC NEWS
Piper Sandler reiterates Glaukos stock rating on growth outlook - Investing.com UK
Piper Sandler reiterates Glaukos stock rating on growth outlook By Investing.com - Investing.com Australia
Why is Glaukos (GKOS) down 14.7% since last earnings report? - MSN
JPMorgan Chase & Co. Has $54.65 Million Stock Position in Glaukos Corporation $GKOS - marketbeat.com
Glaukos Introduces Epioxa, Accelerating Expansion in Corneal Therapy - Bitget
Glaukos Announces Commercial Availability of Epioxa, a Transformative Innovation in Interventional Keratoconus Care - marketscreener.com
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments - Yahoo Finance Singapore
Glaukos (GKOS) Launches Epioxa HD for Keratoconus Treatment - GuruFocus
Glaukos Corporation (NYSE:GKOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Glaukos Announces Commercial Availability of Epioxa for Incision-Free Keratoconus Care - VisionMonday.com
Glaukos SVP Thurman sells $61,968 in GKOS stock By Investing.com - Investing.com India
Navratil, Glaukos corp officer, sells $101k in GKOS stock By Investing.com - Investing.com Australia
Glaukos (NYSE:GKOS) CFO Alex Thurman Sells 625 Shares - MarketBeat
Glaukos SVP Thurman sells $61,968 in GKOS stock - Investing.com
Navratil, Glaukos corp officer, sells $101k in GKOS stock - Investing.com
Glaukos (NYSE: GKOS) CDO reports 1,031-share sale and tax withholding - Stock Titan
Glaukos (NYSE: GKOS) CFO sells 625 shares under 10b5-1 plan - Stock Titan
GLAUKOS (NYSE: GKOS) COO reports tax-withholding of 1,189 vested shares - Stock Titan
[Form 4] GLAUKOS Corp Insider Trading A... - Stock Titan
Glaukos' Epioxa now commercially available in the US - Eyes On Eyecare
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care - BioSpace
Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report? - Yahoo Finance
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional - pharmiweb.com
Glaukos announces commercial availability of Epioxa for the treatment of keratoconus - Optometry Times
Glaukos Corporation Announces Commercial Availability Of Epioxa HD / Epioxa For Keratoconus Treatment - marketscreener.com
Glaukos Launches Epioxa for Keratoconus Treatment - marketscreener.com
Glaukos announces commercial availability of Epioxa HD/Epioxa - TipRanks
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Glaukos Corporation-Aktie (GKOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER |
Mar 24 '26 |
Sale |
105.24 |
1,521 |
160,070 |
46,498 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):